5 results
Primary Objective: To determine whether or not our newly developed MRA with accelerometer can measure the therapy-effect of the MRA by determining the correlation of the treatment-efficacy of an MRA measured by an integrated accelerometer built in…
To compare the efficacy of 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOC leading to healthcare visit, in addition to standard of careTo compare the efficacy of 5.0 mg/kg of crizanlizumab versus placebo on the annualized…
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)